Skip to main content
. 2023 Jul 24;34(11):1793–1811. doi: 10.1681/ASN.0000000000000199

Table 1.

Pharmacology of direct oral anticoagulants and their efficacy in patients with nephrotic syndrome

DOACs Renal Excretion Rate Fecal Excretion Rate Plasma Protein Binding Rate Efficacy in NS
Dabigatran 80% (iv) — 35% Preventing carotid thrombosis in patients with MN28
Apixaban 27% Approximately 50% 87% Preventing thromboembolism in patients with NS.29 But recurrent VTE might occur in patients with MN30
Edoxaban 50% 50% 55% Inhibiting recurred renal VTE in patients with NS after warfarin treatment31
Rivaroxaban 66% 7% 92%–95% Inhibiting VTE in patients with NS with low AT-III level32

DOACs, direct oral anticoagulants; NS, nephrotic syndrome; iv, intravenous injection; MN, membranous nephropathy; VTE, venous thromboembolism; AT-III, antithrombin III.